Login prior to clicking the links below
| Keynote Lecture: The Evolution of Immunotherapy: Past, Present and Future | Hans Hammers | VIEW |
| Science Roundtable: Patient Derived Xenografts of Metastatic Renal Cell Carcinoma to Guide Dose Escalation Regiments and Drug Matching | Matthew Lowerison | VIEW |
| Science Roundtable: Baseline Edmonton Symptom Assessment Scale (ESAS) and Survival in Metastatic Renal Cell Carcinoma (mRCC) | Jeffrey Graham | VIEW |
| Science Roundtable: Genetic Testing for Hereditary Renal Cancer in Ontario: A Preliminary Retrospective Review | Melanie Care | VIEW |
| Science Roundtable: Y-box binding protein 1 is crucial in acquiring drug resistance in advanced renal cell carcinoma | Ninadh D’Costa | VIEW |
| Keynote Lecture: Radical Nephrectomy for Select Masses Amenable to Nephron Sparing Surgery: Therapeutic Heresy or Voice of Reason? | Alexander Kutikov | VIEW |
| Introduction: Future of Canadian kidney cancer surgical trials | Michael Jewett | VIEW |
| Renal Hypothermia Update | Ilias Cagiannos | VIEW |
| Discussion: Future of Canadian kidney cancer surgical trials | Michael Jewett, Ricardo Rendon, Alan So, Ilias Cagiannos | VIEW |
| Blind fight or are we any closer to develop predictive biomarkers for response | Sumanta Pal | VIEW |
| Oligometastatic Debate: Role of SBRT vs. Role of Surgery | Patrick Cheung, Wes Kassouf | VIEW |
| Keynote Lecture: Immunotherapy – ongoing trials / combination therapy | Hans Hammers | VIEW |
| Discussion: Canadian clinical trials discussion (I/O+ combo): What to prioritize? | Anil Kapoor, Georg Bjarnason | VIEW |
| National kidney cancer patient and caregiver survey | Jennifer Jones, Heather Chappell | VIEW |
| Keynote Lecture: Non clear cell – where are we now? | Sumanta Pal | VIEW |
| Germ line mutations | Raymond Kim | VIEW |
| Genomics in RCC – cfDNA and tumor DNA sequencing | Alex Wyatt | VIEW |
| Update Dragon’s Den project: Integrative Sequencing In Germline and Hereditary Tumours (INSIGHT) in non-clear cell RCC | Raymond Kim | VIEW |
| Keynote Lecture: Adjuvant Treatment – A new standard of care and implications on subsequent therapies? | Thomas Powles | VIEW |
| Chromosomal instability in cell-free DNA as plasma biomarkers for renal cell carcinoma | George Yousef | VIEW |
|
Exploiting novel therapeutic targets to block metastasis of clear cell renal cell carcinoma |
Jan K Rudzinski |
VIEW |
|
Predictive Radiomics Signature for treatment response to nivolumab or PD-1/PD-L1 inhibitors in patients with advanced renal cell carcinoma |
Hao-Wen Sim | VIEW |
|
Project Title: Identification of Predictive Biomarkers In Patients With Metastatic Kidney Cancer Using Circulating Tumor DNA Sequencing |
Lucia Nappi | VIEW |
| A Novel Immunotherapeutic Bi-specific T-cell Engager (BiTE) Strategy for RCC | Keith Lawson | VIEW |
| Update Dragon’s Den project: small renal mass biopsy | Tony Finelli | VIEW |
| Keynote Lecture: Surgery of Localized Kidney Cancer: Is a Chance to Cut a Chance to Cure? | Alexander Kutikov | VIEW |
| Keynote Lecture: The Changing Landscape of mRCC | Thomas Powles | VIEW |
| Banquet Dinner Highlights from a distinguished Canadian Oncologist's Career | Peter Venner | VIEW |